STOCK TITAN

BioStem Technologies (BSEM) CEO details over 1.2M shares plus large option grants

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

BioStem Technologies, Inc. disclosed the initial equity holdings of Chief Executive Officer and 10% owner Jason Matuszewski. He directly holds 1,278,433 shares of common stock plus multiple option and RSU awards. These include options over 2,250,000 shares at an exercise price of $2.00 per share, which are fully vested and exercisable, and additional options over 198,807 and 40,427 shares at $10.05 and 440,529 shares at $5.50, vesting over time. He also holds RSUs covering 42,343, 116,550, and 363,636 shares that vest in quarterly installments over three years, each representing a contingent right to receive one share of common stock.

Positive

  • None.

Negative

  • None.
Insider Matuszewski Jason
Role Chief Executive Officer
Type Security Shares Price Value
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F4 -- -- --
holding Restricted Stock Units F6, F5 -- -- --
holding Restricted Stock Units F6, F7 -- -- --
holding Restricted Stock Units F6, F8 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 2,929,763 shares (Direct); Restricted Stock Units — 522,529 shares (Direct); Common Stock — 1,278,433 shares (Direct)
Footnotes (8)
  1. F1. These options are fully vested and exercisable.
  2. F2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  3. F3. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  4. F4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  5. F5. These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
  6. F6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  7. F7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
  8. F8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Direct common shares 1,278,433 shares Common Stock held directly following the reported holdings
Option exercise price $2.00 per share Stock Option (Right to Buy) expiring October 24, 2032 over 2,250,000 underlying shares
Underlying shares at $2.00 2,250,000 shares Fully vested stock options with a $2.00 exercise price
Underlying shares at $10.05 198,807 shares Stock options with $10.05 exercise price expiring March 17, 2035
Underlying shares at $5.50 440,529 shares Stock options with $5.50 exercise price expiring February 11, 2036
RSUs grant 1 42,343 units Restricted Stock Units vesting quarterly over 3 years from September 15, 2024
RSUs grant 2 116,550 units Restricted Stock Units with 33% vested March 17, 2026, then quarterly over two years
RSUs grant 3 363,636 units Restricted Stock Units with 33% vesting February 11, 2027, then quarterly over two years
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with exercise prices and expirations"
Restricted Stock Units financial
"security_title: "Restricted Stock Units" with vesting in equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
vest in equal quarterly installments financial
"These restricted stock units vest in equal quarterly installments over 3 years"

FAQ

What does BioStem Technologies (BSEM) disclose about Jason Matuszewski’s share ownership?

BioStem reports that CEO and 10% owner Jason Matuszewski directly holds 1,278,433 shares of common stock. He also has multiple option and RSU awards giving rights to additional shares, vesting over several years under specified schedules.

What stock options does the BioStem (BSEM) CEO hold according to this filing?

Jason Matuszewski holds options over 2,250,000 shares at $2.00 per share, fully vested and exercisable. He also has options over 198,807 and 40,427 shares at $10.05, and 440,529 shares at $5.50, each with stated expiration dates and vesting schedules.

How do the restricted stock units for BioStem (BSEM) CEO vest?

The filing states RSUs over 42,343, 116,550, and 363,636 shares vest in equal quarterly installments over three years. One grant began vesting September 15, 2024, and others have 33% vesting on specified one-year anniversaries, then quarterly thereafter.

What rights do the BioStem (BSEM) restricted stock units provide the CEO?

Each restricted stock unit represents a contingent right to receive one share of BioStem common stock. Actual shares are delivered as units vest over time, subject to the vesting schedules described in the compensation footnotes.

When do the BioStem (BSEM) CEO’s stock options expire?

Reported option expirations include October 24, 2032 for the $2.00 options, March 17, 2035 and October 13, 2035 for $10.05 options, and February 11, 2036 for $5.50 options. Each option series follows its own vesting schedule before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Matuszewski Jason

(Last)(First)(Middle)
C/O BIOSTEM TECHNOLOGIES, INC.
2836 CENTER PORT CIRCLE

(Street)
POMPANO BEACH FLORIDA 33064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026
3. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock1,278,433D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)10/24/2032Common Stock2,250,000$2D
Stock Option (Right to Buy) (2)03/17/2035Common Stock198,807$10.05D
Stock Option (Right to Buy) (3)10/13/2035Common Stock40,427$10.05D
Stock Option (Right to Buy) (4)02/11/2036Common Stock440,529$5.5D
Restricted Stock Units (5) (5)Common Stock42,343(6)D
Restricted Stock Units (7) (7)Common Stock116,550(6)D
Restricted Stock Units (8) (8)Common Stock363,636(6)D
Explanation of Responses:
1. These options are fully vested and exercisable.
2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
3. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
5. These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
/s/ Jason Matuszewski08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)